Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:13 AM
Ignite Modification Date:
2025-12-25 @ 4:13 AM
NCT ID:
NCT01323920
Eligibility Criteria:
Inclusion Criteria:
* Histologically or cytologically confirmed advanced and/or aggressive hematologic malignancy (including myelodysplastic syndrome) that is unlikely to be cured by alternative therapies
* HLA-Matched unrelated donor; or 1-locus HLA-mismatched related or unrelated donor
* ECOG performance status 0-2
* Adequate organ function
* Able to understand and willing to sign a written informed consent document
* Agrees to practice adequate contraception per study requirements
Exclusion Criteria:
* Pregnant or breastfeeding
* Recipient of prior allogeneic or autologous stem cell transplantation
* Prior abdominal radiation therapy
* HIV-positive on combination antiretroviral therapy
* Seropositive for hepatitis B or C
* Allergies to bortezomib, boron, or mannitol
* Myocardial infarction within last 6 months, NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias
* Uncontrolled bacterial, viral or fungal infections
* Seizures or history of seizures
* History of another non-hematologic malignancy unless disease-free for at least 5 years
* Uncontrolled intercurrent illness
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
60 Years
Study:
NCT01323920
Study Brief:
Protocol Section:
NCT01323920